{"entity":{"id":"ep0062","kind":"drug","name":"EP0062","aka":[],"tldr":"EP0062 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at Androgen receptor.","summary":"EP0062 is a small-molecule drug developed by Ellipses Pharma. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT05573126, plans to enrol 95 participants with primary completion expected 2028-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of EP0062","url":"https://clinicaltrials.gov/search?intr=EP0062"},{"label":"Sponsor page","url":"https://www.ellipses.life"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":[],"companies":["ellipses-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05573126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Small-molecule drug directed at Androgen receptor, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ep0062/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/"}],"trial":[{"id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/"}]}}